Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Accumulated Expenses (2016 - 2025)

Mimedx (MDXG) has disclosed Accumulated Expenses for 15 consecutive years, with $31.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 31.26% to $31.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.1 million through Dec 2025, up 31.26% year-over-year, with the annual reading at $31.1 million for FY2025, 31.26% up from the prior year.
  • Accumulated Expenses hit $31.1 million in Q4 2025 for Mimedx, up from $12.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $31.1 million in Q4 2025 to a low of $9.3 million in Q2 2024.
  • Historically, Accumulated Expenses has averaged $16.6 million across 5 years, with a median of $16.1 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: crashed 68.01% in 2022 and later surged 152.83% in 2024.
  • Year by year, Accumulated Expenses stood at $9.8 million in 2021, then grew by 11.43% to $10.9 million in 2022, then dropped by 14.39% to $9.4 million in 2023, then soared by 152.83% to $23.7 million in 2024, then soared by 31.26% to $31.1 million in 2025.
  • Business Quant data shows Accumulated Expenses for MDXG at $31.1 million in Q4 2025, $12.8 million in Q3 2025, and $15.1 million in Q2 2025.